Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC
ESMO 2022: Highlights, commentary and analysis
ESMO 2022: Breast cancer highlights
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO
Emerging systemic therapies in rare urothelial cancer variants
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer
Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma
Hyperthermic intraperitoneal chemo for locally advanced colon cancer